Solbec soars 70 per cent on cancer drug result

By Staff Writers
Tuesday, 23 November, 2004

Shares in Solbec Pharmaceuticals (ASX:SBP) jumped almost 70 per cent to $0.21 today after preliminary results from a study conducted by the Tumour Immunology Group at the University of Western Australia indicated that the company's cancer drug, Coramsine, was effective in treating and preventing mesothelioma in a mouse model of the cancer.

Mice treated with Coramsine in combination with the immune-triggering compound CpG -- a synthetic DNA fragment containing cytosine and guanine -- showed total remission of the mesothelioma. The therapy also seemed to confer lasting immunity against mesothelioma, as attempts to cause tumour formation in a treated, 'cured' mouse failed.

Coramsine is a mixture of two alkaloids from the prickly weed Solanum linneaum, also known as devil's apple.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd